Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is demonstrating promising data in initial clinical trials . Recent research https://getsocialpr.com/story23148228/retatrutide-emerging-investigations-and-projected-medical-uses